Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.4K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanisms of enhanced antiglioma efficacy of polysorbate 80-modified paclitaxel-loaded PLGA nanoparticles by focused ultrasound.

Journal of cellular and molecular medicine·2018
Same author

Cloning, expression and characterisation of a cysteine protease from Trichinella spiralis.

Folia parasitologica·2018
Same author

Establishment of a Human iPSC- and Nanofiber-Based Microphysiological Blood-Brain Barrier System.

ACS applied materials & interfaces·2018
Same author

Improved design and analysis of CRISPR knockout screens.

Bioinformatics (Oxford, England)·2018
Same author

Boron doping induced thermal conductivity enhancement of water-based 3C-Si(B)C nanofluids.

Nanotechnology·2018
Same author

Trends in Treatment for Prostate Cancer in China: Preliminary Patterns of Care Study in a Single Institution.

Journal of Cancer·2018

Related Experiment Video

Updated: Jun 5, 2025

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

2.3K

Metabolic reprogramming, sensing, and cancer therapy.

Youxiang Mao1, Ziyan Xia1, Wenjun Xia1

  • 1State Key Laboratory of Molecular Oncology, School of Life Sciences, Tsinghua University, Beijing 100084, China; Tsinghua-Peking Center for Life Sciences, Beijing 100084, China.

Cell Reports
|December 13, 2024
PubMed
Summary

Tumor cells reprogram metabolism for survival and immune evasion. Understanding these metabolic changes in the tumor microenvironment (TME) offers new therapeutic strategies for cancer treatment.

Keywords:
CP: Metabolismimmunometabolismmetabolic reprogrammingmetabolite sensingtumor metabolismtumor therapy

More Related Videos

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy
07:20

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

404
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.8K

Related Experiment Videos

Last Updated: Jun 5, 2025

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

2.3K
Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy
07:20

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

404
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.8K

Area of Science:

  • Oncology
  • Cancer Metabolism
  • Immunology

Background:

  • Tumor cells exhibit metabolic reprogramming crucial for survival and proliferation.
  • Tumor cells integrate extracellular/intracellular signals, with nutrient sensing influencing mechanisms.
  • Metabolic alterations in tumor cells contribute to immune evasion within the tumor microenvironment (TME).

Purpose of the Study:

  • To elucidate the mechanisms of metabolic reprogramming in tumor cells.
  • To understand the influence of nutrient sensing on tumor cell adaptation.
  • To explore the role of metabolic changes in immune evasion and TME remodeling.

Main Methods:

  • Review of recent studies on cancer metabolism and TME.
  • Analysis of signaling pathways involved in metabolic adaptation.
  • Investigation of immune cell metabolic education within the TME.

Main Results:

  • Metabolic reprogramming is essential for tumor cell survival, proliferation, and dissemination.
  • Tumor cells metabolically educate immune cells in the TME, promoting immune evasion.
  • Targeting metabolic pathways shows promise as a therapeutic strategy, with enzyme inhibitors in clinical trials.

Conclusions:

  • Understanding tumor metabolic reprogramming and TME remodeling is key for developing novel therapies.
  • Targeting cancer metabolism offers potential for combined metabolic therapy and immunotherapy.
  • Further research into metabolic pathways could unveil new strategies against cancer growth and spread.